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ABSTRACT
The effects of lithium sulphate following acute administration to Wistar rats in therapeutic and toxic
doses were investigated, using as markers the levels and turnover of brain, kidney and liver
nucleotides. Adenine- and guanine-dependent nucleotides were assayed concomitantly, using a high-
performance liquid chromatographic method. Following acute administration, lithium’s effects on 3’,5’-
cAMP levels were more significant at hepatic and cerebral level, in a dose-dependant manner. The
effect on 3’,5’-cGMP had tissue specificity and was not dose-dependant. It might be possible that 3’,5’-
cGMP is a better indicator of lithium toxicity than 3’,5’-cAMP.
INTRODUCTION
Lithium is used as a major drug in psychiatry, especially in the treatment and prophylaxy of
bipolar affective disorder, also in antidepressant-resistant patients, as well as in intemal medici-
ne.Despite almost 40 years of clinical use and scientific investigation, neither the pharmacological
actions of lithium at therapeutic doses, nor its mechanisms of toxicity have yet been completely
established.
According to the most recent theories, the pharmacological and some of the toxic effects of
lithium are related to its interaction with the signal transduction pathways5’. Li has been shown to
interfere both with G-proteins and with the turnover of second messengers like 3’,5’-cAMP, 3’,5’-cGMP
and the molecules dedved from phosphatidylinositol 4,5-bisphosphate (PIP2) pathway7-.
Generally, lithium is known to inhibit the adenylate cyclase (AC) which catalyses the formation
of 3’,5’-cAMP, a second messenger. The differential inhibition of receptor-specific AC species could
provide an unifying hypothesis for the therapeutic and adverse effects of the drug5. Thus, the inhibition
of adrenoceptor-activated cyclase at low lithium concentration could be seen as therapeutic effect, while
the inhibition of other systems, e.g. dopamine-stimulated, ADH-stimulated and TSH-stimulated cyclase
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Lithium effect on 3’,5’-cGMP was studied only in the brain and at therapeutic doses, without
correlating the results with the effects on other cyclic nucleotides5’
Considering the role of the second messengers in the developement of toxic phenomena, we
investigated the effects of lithium sulphate following acute administration to Wistar rats, at therapeutic
and toxic doses, using as markers the level and tumover of brain, kidney and liver nucleotides.
MATERIALS AND METHODS
Animals. Four groups of male Wistar rats (body weight 240+25g) (provided by Animal Breeding
Station, UMF Cluj-Napoca) were used, standard food and microclimate conditions being provided
before and dudng the experiments.
Treatment. Lithium sulphate was dissolved in distilled water and given orally by intubation.
Three doses 2 (group B), 6 (group C) and 10 (group D) mmol Li*/kg body weight were applied by
single administration to experimental groups. Controls (group A) received distilled water.
Sampling. All the animals were sacdfied 48 hours after the treatment and immediately the
whole brain, kidney and liver were taken on ice for nucleotide assay.
Extraction of nucleotides from all tissues was performed according to Perret method2, by
protein precipitation with tdchloroacetic acid 10%, centdfugation and neutralization of supematant with
potassium hydroxide 1M. The lipids were removed by extraction with diethylether, before acid
precipitation.
Nucleotide separation was performed using a combination of two HPLC methods3’. The
separation was performed with a gradient HPLC system, using two Altex 101 pumps, an ODS column
(200 x 4 mm i.d.and 5 Im particle diameter), a UV-VIS Kontron Instruments detector, coupled to a
Hewlett Packard 3650 integrator. All chromatograms were registered at 254 nm. The flow rate of mobile
phases was 1,5 ml/min and the elution of the samples was performed with a step-gradient of 0.05 M
NHH2PO (solvent A, pH=6) (0 7.5 min) and a mixture 90:10 of 0.05 M NH4H2PO Methanol
(Solvent B, pH=5.5) ( 7.5 14 min).
Reagents. Reagent-grade nucleotides (GTP, GDP, ATP, ADP, 5’-AMP, 3’-AMP, 3’,5’-cAMP,
3’,5’-cGMP) and NH,H2PO, were purchased from Sigma and methanol of HPLC purity from Merck.
RESULTS AND DISCUSSION
The identification of the nucleotides in the biological samples was done according to their
retention time (tR) and the order of elution comparared with standards’ separation (Fig.l). Co-
chromatograms of each sample with different standard nucleotides were also performed for a better
identification of peaks.
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For the quantitative analysis, the chromatographic peaks were integrated and from their area,
the percentage of each nucleotide was determined.
Figure 1. HPLC separation of nucleotide standards GTP ( tR =1.40 min ), GDP (tR =1.96 min ), ATP
(tR=2.53 min), ADP (tR=4.28 min), 5’AMP (tR=9.21 min), 3’AMP (tR=9.60 min), 3’,5’-cGMP (tR=l 1.21
min) and 3’,5’-cAMP (tR=12.52 min ).
The validation of the extraction technique was done by calculating the energy charge (EC) of
the cells12:
EC [ATP] + 1 / 2[ADP]
[ATP] + [ADP]-4- [AMP]
Most of the cells in a normal energy status have EC between 0.80 and 0.955. For all our tissue samples
EC oscillated between 0.80 and 0.92, indicating a good preparation of the extracts and, in the same
time proving that lithium did not significantly modify the global energy status of the cells.
Fig.2 shows the separation of adenine- and guanine nucleotides from brain extracts. In controls
(Fig.2.A.) the following nucleotides were identified: GTP co-eluted with GDP, ATP, ADP, 5’-AMP, 3’-
AMP and 3’,5’-cGMP. The signal with tR= 12.33 min corresponding to 3’,5’-cAMP in standard mixture
was not present in this extract. Taking into account the fact that only basal, unstimulated AC activity was
investigated and 3’,5’-cAMP (whose levels are normally below 10
.6 M) is metabolized within seconds to
5’-AMPe’7, we considered that the effect of lithium on this second messenger could be appreciated only
by the variation of 5’-AMP levels. Li2SO4 administration at increasing doses (from 2 to 10 mmol/kg)
resulted in the disappearance of the peak with tR= 9.92 min (corresponding to 3’,5’-cGMP) and a
decrease of the peak surface with tR= 9.09 min, corresponding to 5’-AMP (Fig.2 B,C,D).
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Figure 2. HPLC separation of nucleotides in brain homogenates, before (A) and after oral
administration of 2 (B), 6 (C) and 10 (D) mmol Li/kg b.w.
The HPLC separation of adenine- and guanine nucleotides from kidney homogenates is
depicted in Fig.3. From the controls’ chromatograms were identified" GTP co-eluted with GDP, ATP,
ADP, 5’-AMP, 3’-AMP and 3’,5’-cGMP (Fig.3.A). In the chromatograms from Li2SO,-treated rats an
increase of the surface of the peaks with tR= 9.32 min (corresponding to 3’-AMP) and with tR=9.93
minutes, (corresponding to 3’,5’-cGMP) was observed (Fig.3 B,C,D).
Figure 3. HPLC separation of nucleotides in kidney homogenates,
administration of 2 (B), 6 (C) and 10 (D) mmol Li/kg b.w.
before (A) and after oral
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Fig.4 shows the separation of adenine- and guanine nucleotides from liver homogenates. In controls
(Fig.4.A) the following nucleotides were identified GTP co-eluted with GDP, ATP, ADP, 5’-AMP, 3’-
AMP and a small peak corresponding to 3’,5’-cGMP. In the chromatograms from Li2SO4-treated animals
(Fig.4 B,C,D) the increase of the peak area corresponding to 3’,5’-cGMP and a gradual decrease until
disappearance of the peak with tF=9.12 min, (corresponding to 5’-AMP) was observed.
Figure 4. HPLC separation of nucleotides in liver homogenates, before (A) and after oral administration
of 2 (B), 6 (C) and 10 (D) mmol Li/kg b.w..
The tumover of nucleotides in brain, kidney and liver is presented in Fig. 5, 6 and 7. The dose of 2
mmol/kg Li induced the increase of ATP levels in brain (Fig.5), while the doses of 6 mmol/kg and 10
mmol/kg decreased in a smaller extent the levels of 5’-AMP. An inhibition of 3’,5’-cGMP formation was
observed for all Li doses. No significant variations of nucleotides were observed in kidney (Fig 6)
except the levels of 3’,5’-cGMP, which were 4-5 times increased folowing all Li doses. Fig.7 shows that
Li/, in all doses, in liver increased 5-6 times the 3’,5’-cGMP levels while the doses of 6 and 10 mmol
Li//kg inhibited the formation of 5’-AMP.
Unlike other studies, where the analysis of the cyclic nucleotides was performed by
18-20 mdioimmunoassay methods our method allowed the concomitant separation and evaluation of both
adenine- and guanine-dependant nucleotides in tissues. Although 3’,5’-cAMP was not identified in these
tissues, dose-dependent variations in the levels of its stable metabolite, 5’-AMP were observed. So, the
acute administration of lithium induced a decrease of 5’-AMP levels in brain, which is more important
when the dose of 2 mmol Li//kg ( extrapolated from the human therapeutic doses) was administered.
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Figures 5-6-7. Tumover of adenine- and
guanine nucleotides in rat brain (5), kidney
(6) and liver (7) before (Control) and after
oral administration of 2,6 and 10 mmol Li/kg
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This might reflect an inhibition of the basal adenylate cyclase activity. In some studies the results were
similar, while in others the basal enzyme activity was reported to decrease only after chronic
administration of lithium.
Unlike other results obtained in chronic experiments, where an antagonistic relationship
between 3’,5’-cAMP and 3’,5’-cGMP after Li treatment was reported, in our study all Li doses inhibited
the formation of 3’,5’-cGMP in brain concomitantly with the decrease of 3’,5’-cAMP levels (Fig.5).
These differences could be explained by the different type of administration (acute treatment) and
assessement of cyclic nucleotides. In the same time, our results are in good agreement with the
experiments of Kanba and Richelson
2 using cultured neuroblastoma cells, where the formation of 3’,5’-
cGMP was mediated by muscadnic receptors and inhibited in a dose-dependant fashion by increasing
doses of LiCI above lmM. These authors pointed out that some of lithium toxic effects resemble
atropine poisoning and might be due to its antimuscadnic effects at the level of the receptor.
A significant increase of 3’,5’-cGMP levels was observed in kidney, in all Li/-treated groups
while the 5’-AMP levels were not significantly affected by acute lithium administration (Fig.6).
The most important changes in the percentage of adenine- and guanine-dependent nucleotides
were observed at the hepatic level, in a dose-dependant manner. Doses of 2 mmol Li//kg had a reduced
effect on 3’,5’-cAMP level, while the toxic doses of 6 and 10 mmol Li//kg inhibited the formation of 3’,5’-
cAMP (Fig.7). The explanation could be due to hepatocyte’s specificity, with a high metabolic tumover,
more susceptible comparatively to other organs.
Our study confirmed that the stimulation of 3’,5’-cGMP formation by lithium might have
important implications in its mechanism of toxicity. It is supposed that Li may increase 3’,5’-cGMP via
modulation of the free fatty acids and their oxidized metabolites, especially prostaglandine 52 and the
associated free radicals which are known to activate guanylate cyclase.
Following acute administration, lithium’s effects on 3’,5’-cAMP were more significant at hepatic
and brain level in a dose-dependant manner, while the effects on 3’,5’-cGMP were different from brain
to liver and kidney, respectively and were not dose-dependant. Thus, the relationships between 3’,5’-
cGMP and 3’,5’-cAMP were dependant on the. tissue investigated and in consequence, on the receptors
and neurotransmiters involved.
Considering the different tumovers of 3’,5’-cGMP and 3’,5’-cAMP in different tissues, we
suggest their use as relevant markers of lithium activity. Taking into account the most significant
variations of 3’,5’-cGMP in all investigated tissues, it might be prefered as a better indicator of lithium
toxicity.
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